Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CDXS

CDXS - Codexis Inc Stock Price, Fair Value and News

$1.30-0.13 (-9.09%)
Market Closed

14/100

CDXS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

14/100

CDXS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.34

Target 3M

$1.51

Target 6M

$1.43

CDXS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CDXS Price Action

Last 7 days

-24.0%

Last 30 days

-20.7%

Last 90 days

-44.9%

Trailing 12 Months

-71.6%

CDXS RSI Chart

CDXS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CDXS Valuation

Market Cap

117.4M

Price/Earnings (Trailing)

-1.84

Price/Sales (Trailing)

2.22

EV/EBITDA

-2.37

Price/Free Cashflow

-1.9

CDXS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.34

Target 3M

$1.51

Target 6M

$1.43

CDXS Fundamentals

CDXS Revenue

Revenue (TTM)

52.9M

Rev. Growth (Yr)

-32.98%

Rev. Growth (Qtr)

-43.89%

CDXS Earnings

Earnings (TTM)

-64.0M

Earnings Growth (Yr)

4.97%

Earnings Growth (Qtr)

-47.79%

CDXS Profitability

EBT Margin

-120.76%

Return on Equity

-165.92%

Return on Assets

-51.59%

Free Cashflow Yield

-52.51%

CDXS Investor Care

Shares Dilution (1Y)

10.99%

Diluted EPS (TTM)

-0.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202549.8M57.2M52.9M0
202474.2M60.9M64.4M59.3M
2023116.2M99.1M74.0M70.1M
2022122.1M135.0M132.7M138.6M
202172.4M82.9M101.3M104.8M
202067.5M70.2M66.7M69.1M
201962.1M60.9M65.9M68.5M
201856.1M59.3M66.2M60.6M
201748.8M43.2M38.3M50.0M
201643.0M53.0M50.5M48.8M
201535.0M34.5M44.4M41.8M
201427.5M27.1M30.6M35.3M
201368.6M52.7M30.3M31.9M
2012124.0M120.8M113.9M88.3M
2011112.4M114.0M120.2M123.9M
2010000107.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Codexis Inc

CDXS
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
 CEO
 WEBSITEcodexis.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES248

Codexis Inc Frequently Asked Questions

CDXS is the stock ticker symbol of Codexis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Codexis Inc is 117.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CDXS's fair value in chart for subscribers.

The fair value guage provides a quick view whether CDXS is over valued or under valued. Whether Codexis Inc is cheap or expensive depends on the assumptions which impact Codexis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDXS.

As of Wed Jan 28 2026, CDXS's PE ratio (Price to Earnings) is -1.84 and Price to Sales (PS) ratio is 2.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDXS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Codexis Inc has provided -0.107 (multiply by 100 for percentage) rate of return.